Sands Capital: 13 Bio-Techne transactions (Sands Capital Management

13 Sands Capital Bio-Techne Trades

Sands Capital's position in Bio-Techne is currently worth $1.07 Million. That's 0.00% of their equity portfolio (60th largest holding). The first Bio-Techne trade was made in Q1 2021. Since then Sands Capital bought shares nine more times and sold shares on three occasions. The investor's estimated purchase price is $3.38 Million, resulting in a loss of 68%.

Avg closing price

Price range

Increased shares by 1.4% (+178 shares) Q1 2024

Avg closing price $71.55

Price range $65.98 - $77.09

Increased shares by 31.7% (+3.02 Thousand shares) Q4 2023

Avg closing price $65.87

Price range $52.83 - $78.22

Increased shares by 26.0% (+1.96 Thousand shares) Q3 2023

Avg closing price $79.00

Price range $67.52 - $89.42

Sold 99.0% shares (-740 Thousand shares) Q2 2023

Avg closing price $80.38

Price range $73.76 - $85.98

Increased shares by 1.5% (+10.9 Thousand shares) Q1 2023

Avg closing price $77.07

Price range $71.62 - $86.62

Increased shares by 307.5% (+556 Thousand shares) Q4 2022

Avg closing price $230.67

Price range $80.67 - $352.29

Increased shares by 13.5% (+21.5 Thousand shares) Q3 2022

Avg closing price $345.64

Price range $282.54 - $391.85

Sold 4.0% shares (-6.66 Thousand shares) Q2 2022

Avg closing price $374.87

Price range $322.67 - $449.65

Increased shares by 70.7% (+68.7 Thousand shares) Q1 2022

Avg closing price $412.68

Price range $353.85 - $487.79

Sold 1.9% shares (-1.93 Thousand shares) Q4 2021

Avg closing price $490.35

Price range $456.15 - $525.06

Increased shares by 1.2% (+1.22 Thousand shares) Q3 2021

Avg closing price $486.80

Price range $444.87 - $538.88

Increased shares by 12.7% (+11.1 Thousand shares) Q2 2021

Avg closing price $421.02

Price range $387.35 - $450.26

New holding (+86.9 Thousand shares) Q1 2021

Avg closing price $364.91

Price range $314.62 - $411.00

News about Bio-Techne Corp and Sands Capital

What Makes Bio-Techne Corporation (TECH) an Investment Bet?

Polen Capital, an investment management company, released its “Polen U.S. SMID Company Growth Strategy” fourth-quarter 2023 investor letter. A copy of the sa...

Insider Monkey, 3 months ago

Bio-Techne Co. (NASDAQ:TECH) Shares Acquired by SRS Capital Advisors Inc.

… of Bio-Techne Co. (NASDAQ: TECH – Get Rating) by 305.6% … . Analysts Set New Price Targets TECH has been the subject of … 4.04. Bio-Techne (NASDAQ: TECH – ...

EIN News Tech, 11 months ago

BIO-TECHNE TO PRESENT AT THE 2023 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE

MINNEAPOLIS, May 12, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial...

PR Newswire, about 1 year ago